Hepatitis B vaccine Engerix

Hepatitis B Vaccine (Engerix-B, Recombivax HB) Human Papillomavirus (Types 6,11, 16,18) Recombinant Vaccine (Gardasil)... [Pg.50]

Hepatitis B Vaccine (Engerix-B, Recombivax HB) [Vaccine/ Inactivated] Uses Prevent Hep B Action Active immunization recombinant DNA Dose Adults. 3 EM doses 1 mL each 1st 2 doses 1 mo apart the 3rd 6 mo after the 1st Peds. 0.5 mL EM adult schedule Caution [C, +] 1 effect w/ immunosuppressives Contra Yeast allergy Disp Engerix-B Inj 20mcg/mL peds inj 10 mcg/0.5 mL Recombivax HB Inj 10 40 mcg/mL peds inj 5 mcg/0.5 mL SE Fever, inj site pain Interactions i Immune response W/ corticosteroids, immunosuppressants EMS None OD Unlikely... [Pg.183]

Hepatitis B vaccine Engerix-B (GlaxoSK) Recombivax HB (Merck) Hepatitis B prophylaxis... [Pg.274]

Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B) A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003 63 1021-1051. [Pg.758]

The two hepatitis B vaccines available in the United States are Recombivax HB and Engerix-B. These vaccines are produced with recombinant DNA technology by inserting the gene for HBsAg into the plasmid that is synthesized by Saccharomyces cerevisiae cells. Both vaccines are effective in providing... [Pg.352]

The same name is also being used for some vaccines that differ in potency. As shown in Table 1.4, the two approved vaccines against hepatitis B, Recombivax HB and Engerix-B, both known as Hepatitis B Vaccine (Recombinant), when used as directed, are therapeutically equivalent in terms of their ability to induce antibodies that protect vaccinated individuals from hepatitis B virus infection. However, the dose and volume required to produce a satisfactory immune response are different for each product and for each age group. [Pg.10]

Engerix-B Hepatitis B vaccine GlaxoSmithKline 8/1989 Hepatitis B 5. cerevisiae CHO... [Pg.1423]

Juvenile chronic polyarthropathy (62) and reactive arthritis (63) have been attributed to hepatitis B vaccine. Erythema nodosum and polyarthritis occurred the day after Engerix-B vaccine administration (64). The authors referred to reports of three other cases of polyarthritis in the literature. [Pg.1606]

Reports on adverse events after the administration of the two hepatitis B vaccines licensed in the US (Engerix-B and Recombivax HB) have been compared in two different surveillance systems VAERS and Vaccine Safety Datalink (VSD) (8). VSD is a computerized record linkage system designed to allow more rigorous evaluation of... [Pg.3552]

The two recombinant hepatitis B vaccine products available in the United States (Recombivax HB, Merck Engerix-B, SmithKline Beecham) have comparable immune responses and safety profiles. The vaccines contain 5 to 40 meg HBsAg protein per milliliter adsorbed onto aluminum. Neither brand of hepatitis B vaccine contains thimerosal. The recent availability of a combined HAV and HBV vaccine allows for a more accelerated schedule for immunization. For a more detailed comparison of the potential vaccination schedules refer to the cited reference. These vaccines are some of the safest available. Side effects of the vaccine are soreness at the injection site, headache, fatigue, irritability, and fever. The number of patients experiencing adverse reactions decreases with each vaccine dose, and adverse reactions are less common in infants and children than in adults. There is no association between Guillain-Barre syndrome and the recombinant vaccine, and the vaccine does not transmit HIV. The hepatitis B vaccine is contraindicated for patients with anaphylaxis to... [Pg.750]

Engerix B Genentech Smith Klein Beecham Hepatitis B Vaccination 584 568... [Pg.194]

Two hepatitis B vaccines, Recombivax HB and Engerix-B, were marketed in 1986 and 1989 respectively. Both are derived from a hepatitis B surface antigen and are produced in yeast cells. The primary difference between the two appears to be in exact dosing regimens. The immunization regimen consists of three injections initial, at 1 month, and at 6 months. The immune response and clinical reactions for both intramuscular and subcutaneous administration are... [Pg.236]

Hepatitis B vaccine, recombinant (Surface (Engerix-B Recombivax HB) antigen of... [Pg.347]

Engerix B (tradename) is a subunit vaccine containing purified recombinant hepatitis B surface antigen (HBsAg) that gained approval in the USA in 1998. It is indicated for active immunization against infection caused by all known serotypes of hepatitis B virus. [Pg.405]

The protective efficacy of Engerix B has been demonstrated in a number of trials, in the context of infants, children and adults. Seroprotection rates (measured as serum anti-hepatitis B antibody titres above a value of 10 mlU ml-1) of over 95 per cent were usually recorded. The product was found to be generally well tolerated. The most frequently reported adverse effects were local reactions at the injection sites, fever, headache and dizziness. Special consideration to risk benefit ratio should be given to MS patients, as exacerbations of this condition have been (rarely) reported following administration of hepatitis B and other vaccines. Engerix B is manufactured and marketed by GlaxoSmithKline. [Pg.405]

Vaccines made with recombinant proteins marshal an immune response to specific viruses to treat or prevent disease. Vaccines to prevent infection with the liver-damaging hepatitis viruses (Twinrix , Recombivax HB , and Engerix-B ) include a recombinant version of a hepatitis virus B protein. Recombinant hepatitis B protein is also included in some combination vaccines given to children. Comvax also includes a recombinant flu virus protein. [Pg.77]

Engerix B (rHBsAg produced in S. cerevisiae) SmithKline Beecham Vaccination against hepatitis B... [Pg.442]

Recombivax (Merck), Engerix B (Smith-Kline Beecham) and Bimmugen (Kaketsuken) are the commercial hepatitis B virus (HBV) vaccines. This is the first recombinant human vaccine to receive approval world... [Pg.100]

Hepatitis B surface antigen Monomer consists of 226amino acids Engerix B (SmithKIine Beecham) HB-Vax II (Aventis Pasteur) Yeast Mammalian cells Vaccination... [Pg.431]

In 1987, protein engineering enabled scientists to create two vaccines for hepatitis B Engerix-B and Recombivax. [Pg.1542]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...